Iterum Therapeutics reports Q1 non-GAAP EPS (10c) vs. (38c) last year

“Based on pre-commercialization work completed to date, we expect to be able to launch ORLYNVAH for the treatment of uncomplicated urinary tract infections by the fourth quarter of this year,” said Corey Fishman, Iterum’s Chief Executive Officer. “While we continue to pursue our strategy of seeking a strategic transaction acceptable to our Board, there is an urgency to bring ORLYNVAH to the U.S. market to serve patients suffering with uUTIs who have limited or no treatment options given the lack of innovation over the past 25 years and the increasing rate of antimicrobial resistance to the generic drugs used to treat uUTIs today.”